Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association

April 27, 2009
4 mins read

The FINANCIAL — Schering-Plough Corporation (NYSE: SGP) on April 27 reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights.

 

The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.

 

"Physicians are constantly looking for ways to improve hepatitis C treatment outcomes by increasing response rates or reducing side effects and making treatment more tolerable for their patients," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "We undertook these large PEGINTRON studies to help investigators address these important clinical issues. Conducting these studies demonstrates Schering-Plough's longstanding commitment to investigating potential new treatment strategies for patients with hepatitis C."

 

"Combination therapy with peginterferon and ribavirin is a recognized standard of care worldwide for treating chronic hepatitis C virus (HCV) infection. Patients with HCV genotype 1, the most common and hardest to treat form of hepatitis C, are typically treated for 48 weeks, while patients with HCV genotypes 2 or 3 are treated for 24 weeks," Schering-Plough reports.

 

The aim of the three PEGINTRON studies was to evaluate investigational regimens in these patient populations compared to current standard practice.

 

Key Findings

 

PEGINTRON Maintenance Therapy in Cirrhotic (Metavir F4) HCV Patients Who Failed to Respond to Interferon/Ribavirin (IR) Therapy: Final Results of the EPIC3 Cirrhosis Maintenance Trial(1)

 

The large EPIC3 clinical study program includes a prospective trial designed to assess the efficacy and tolerability of long-term, low-dose maintenance therapy with PEGINTRON 0.5 mcg/kg/week in patients who previously failed treatment with any alfa-interferon plus ribavirin combination therapy. A total of 631 patients were randomized to PEGINTRON or observational control. Of these, 454 patients were from the retreatment study portion of the EPIC3 program and 172 were direct enrollers into the maintenance study. The primary efficacy measure for the study was time to development of first clinical event, defined as liver decompensation (variceal bleeding, Child-Pugh class C, grade 2 or higher hepatic encephalopathy, ascites requiring therapeutic paracentesis and/or additional therapy), development of hepatocellular carcinoma (HCC), liver transplantation or death. All events other than transplantation and death were adjudicated by an independent committee of experts blinded to the study arm. The secondary efficacy analyses included time to disease progression, including additional events of Child-Pugh class B, emergence of varices and enlargement of pre-existing varices requiring additional therapy.

 

In the primary efficacy analysis, 36 patients in the control arm and 27 in the treatment arm had clinical events (P=0.14), a non-statistically significant difference. However, in the secondary efficacy analysis there were 87 clinical events in the control arm and 63 in the treatment arm (P=0.01), a statistically significant difference. The main events causing the difference on secondary analysis were emergence or enlargement of varices (43 control vs. 16 treatment). In patients with pre-existing esophageal varices (n=82) there were significantly more events (n=14) in the observation arm compared to the treatment arm (n=4) (P=0.01). Overall the safety profile for PEGINTRON was similar to that in previous studies; however, there were more serious infections in the treatment group (25 vs. 3), although these were not linked to neutropenia. None were unexpected events, nor was there a pattern to them.

 

In the primary analysis, PEGINTRON maintenance therapy was not superior to observational control in preventing the occurrence of clinical events. However, there was a statistically significant reduction in clinical events of hepatic decompensation on protocol-defined secondary analysis as well as in subjects with pre-existing esophageal varices.

 

Extended Treatment Duration in Chronic Hepatitis C Genotype 1-Infected Slow Responders: Final Results of the SUCCESS Study(2)

 

The primary objective of the SUCCESS study was to evaluate the effect of extending treatment duration to 72 weeks with PEGINTRON and REBETOL(R) (ribavirin, USP) combination therapy in genotype 1-infected patients who have slow response to therapy, defined as having detectable virus (HCV RNA) with at least a 2 log10 reduction in viral load at treatment week 12 and undetectable virus at treatment week 24. In this large, prospective, randomized, multinational clinical trial, slow responders were randomized at treatment week 36 to receive PEGINTRON combination therapy for a total of 48 weeks (n=86) (standard approved duration) or 72 weeks (n=73). Patients with undetectable virus at week 12 (complete early virologic response), received treatment for 48 weeks (n=816), whereas patients who did not respond to treatment (less than a 2 log10 reduction in viral load at week 12) were discontinued from the study. In total, 1,419 patients were treated.

 

In this study, sustained virologic response (SVR)(3) with 72-week treatment was not statistically superior to the 48-week treatment in slow responders (47.9 percent (35/73) vs. 43.0 percent (37/86), respectively), the primary endpoint of the study. Relapse rates between these two arms also were not significantly different (32.7 percent (16/49) vs. 47.1 percent (32/68), respectively) and adverse events were similar among treatment groups (secondary endpoints). Early discontinuation rates were higher in the 72-week arm compared to the 48-week arm (23.3 percent (17/73) vs. 9.3 percent (8/86), respectively).

 

Reduced Dose and Duration of Peginterferon Alfa-2b + Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial)(4)

 

Shorter duration treatment of patients chronically infected with HCV genotype 2 or 3 (G2/3) with peginterferon and ribavirin has been largely unsuccessful compared with standard-duration treatment (24 weeks). The implications of a reduced peginterferon dose in G2/3 patients were unknown. The primary objective of the REDD 2/3 study was to evaluate the effect of reduced treatment duration or a reduced PEGINTRON dose on SVR and relapse rates among treatment-naive G2/3 patients in an international, multicenter, non-inferiority study. The study began as a real-world, investigator-initiated study conducted in Germany and then the patient population was expanded to include centers in Europe and Asia-Pacific. In total, 682 patients were treated. Of these, 80.2 percent were G3 and 53.1 percent had high baseline viral load (greater than or equal to 600,000 IU/mL), both negative factors for achieving SVR.

 

Eligible patients were randomized to one of three arms: (A) PEGINTRON (1.5 mcg/kg/wk) for 24 weeks (approved dose), (B) PEGINTRON (1.0 mcg/kg/wk) for 24 weeks (low dose) or (C) PEGINTRON (1.5 mcg/kg/wk) for 16 weeks (short duration), each in combination with weight-based REBETOL (800-1200 mg/day). Co-primary end points were non-inferiority between arms A and B and A and C. SVR rates overall were (A) 66.5 percent (153/230), (B) 64.3 percent (144/224) and (C) 56.6 percent (129/228). Neither co-primary endpoint was met. Relapse rates were lower with 24 weeks compared to 16 weeks of therapy (17.8 percent (29/163) and 16.3 percent (27/166) vs. 29.3 percent (49/167), respectively). Adverse events were similar, regardless of treatment duration or PEGINTRON dose.

 

 

Leave a Reply

Related stories


Fatal error: Uncaught Error: Call to a member function have_posts() on null in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php:731 Stack trace: #0 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/widget.php(273): fox56_blog_list() #1 /home/slonfcxh/public_html/wp-content/themes/fox/widgets/latest-posts/register.php(33): include('/home/slonfcxh/...') #2 /home/slonfcxh/public_html/wp-includes/class-wp-widget.php(394): Wi_Widget_Latest_Posts->widget() #3 /home/slonfcxh/public_html/wp-includes/widgets.php(847): WP_Widget->display_callback() #4 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(418): dynamic_sidebar() #5 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(136): fox56_single_sidebar() #6 /home/slonfcxh/public_html/wp-content/themes/fox/data/single.php(7): fox56_single_inner() #7 /home/slonfcxh/public_html/wp-content/themes/fox/single.php(23): fox56_single() #8 /home/slonfcxh/public_html/wp-includes/template-loader.php(132): include('/home/slonfcxh/...') #9 /home/slonfcxh/public_html/wp-blog-header.php(19): require_once('/home/slonfcxh/...') #10 /home/slonfcxh/public_html/index.php(17): require('/home/slonfcxh/...') #11 {main} thrown in /home/slonfcxh/public_html/wp-content/themes/fox/data/archive.php on line 731